There were some promising new treatment for ccRCC including programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors and so on while these immunotherapies were limited by low long-term response rates and lack of reliable prognostic factors [30]. This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.